Clene (CLNN) has released an update.
The Company recently announced a major breakthrough, revealing that its CNM-Au8® treatment has shown a substantial survival benefit in ALS EAP compassionate use programs. This promising development has garnered attention and could potentially be of great interest to investors monitoring advancements in the healthcare sector.
For further insights into CLNN stock, check out TipRanks’ Stock Analysis page.
